

## Manitoba Biosimilars Initiative

### Completed Biosimilar Transition Periods

Drug Name	Reference Biologic (Switch from)	Biosimilar (Switch to)	Health Conditions*	Transition Period End Date
<b>Denosumab</b>	Prolia	Jubbonti	Osteoporosis	May 27, 2025
<b>Denosumab</b>	Xgeva	Wyost	Prevention of skeletal-related events (SREs)	May 27, 2025
<b>Ustekinumab</b>	Stelara	Jamteki Steqeyma Wezlana	Plaque Psoriasis	May 27, 2025
<b>Adalimumab</b>	Humira	Abrilada Amgevita Hadlima Hulio Hyrimoz Idacio Simlandi Yuflyma	Ankylosing Spondylitis Crohn's Disease Hidradenitis Suppurativa Plaque Psoriasis Polyarticular Juvenile Idiopathic Arthritis Psoriatic Arthritis Rheumatoid Arthritis Ulcerative Colitis	January 31, 2025

<b>Drug Name</b>	<b>Reference Biologic (Switch from)</b>	<b>Biosimilar (Switch to)</b>	<b>Health Conditions*</b>	<b>Transition Period End Date</b>
<b>Enoxaparin</b>	Lovenox	Elonox Elonox HP Inclunox Inclunox HP Noromby Noromby HP Redesca Redesca HP	Prevention and treatment of venous thromboembolic events	January 31, 2025
<b>Etanercept</b>	Enbrel	Brenzys Erelzi Rymti	Ankylosing Spondylitis Plaque Psoriasis Polyarticular Juvenile Idiopathic Arthritis Psoriatic Arthritis Rheumatoid Arthritis	January 31, 2025
<b>Filgrastim</b>	Neupogen	Grastofil Nivestym Nypozi	Prevention and treatment of neutropenia	January 31, 2025
<b>Glatiramer</b> (a non-biologic complex drug)	Copaxone	Glatect	Multiple Sclerosis	January 31, 2025
<b>Infliximab</b>	Remicade	Avsola Inflectra Renflexis	Ankylosing Spondylitis Crohn's Disease Plaque Psoriasis Psoriatic Arthritis Rheumatoid Arthritis Ulcerative Colitis	January 31, 2025
<b>Insulin aspart</b>	NovoRapid	Kirsty Trurapi	Diabetes	January 31, 2025

<b>Drug Name</b>	<b>Reference Biologic (Switch from)</b>	<b>Biosimilar (Switch to)</b>	<b>Health Conditions*</b>	<b>Transition Period End Date</b>
<b>Insulin glargine</b>	Lantus	Basaglar Semglee	Diabetes	January 31, 2025
<b>Insulin lispro (100 units/mL)</b>	Humalog	Admelog	Diabetes	January 31, 2025
<b>Rituximab</b>	Rituxan	Riximyo Ruxience Truxima	Granulomatosis with Polyangiitis Microscopic Polyangiitis Rheumatoid Arthritis	January 31, 2025

**Please note:**

- Coverage of Humalog 200 units/mL will continue to be available for patients who need a higher concentration formula, as there is no equivalent biosimilar version available at this time.
- Coverage of Lantus cartridges will continue to be available for pediatric patients who require a half-unit pen device to administer insulin glargine.
- Coverage of NovoRapid vials will continue to be available for patients who use vials for an insulin pump, while biosimilars undergo insulin pump certification, and until these biosimilar(s) in a vial format are available / listed on the Manitoba Drug Benefits Formulary.
- Admelog is compatible with various insulin pump models from Insulet (Omnipod), Medtronic, Tandem, and Ypsomed.
- Individuals with questions about insulin compatibility with specific insulin pump models are encouraged to contact the insulin pump manufacturer.